Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × NSCLC × anlotinib × Clear all

Phase

Status

Unknown 3 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 6 Small Cell Lung Carcinoma 5 Thyroid Neoplasms 2 Sarcoma 2 Lung Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Small Cell Lung Cancer Extensive Stage 1 Proteinuria 1 Platinum-resistant Ovarian Cancer (PROC) 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neoplasms 1 NSCLC 1 Melanoma 1 Limited Stage Small Cell Lung Cancer 1 Extensive Stage Lung Small Cell Cancer 1 Esophageal Neoplasms 1 Carcinoma, Renal Cell 1 Breast Neoplasms 1 Brain Neoplasms 1 Biliary Tract Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

Surgical Procedures, Operative 2 Drug Therapy 2 Carboplatin 2 toripalimab 1 tislelizumab 1 surufatinib 1 osimertinib 1 lorlatinib 1 anlotinib 1 Radiotherapy 1 Radiosurgery 1 Platinum Compounds 1 Pemetrexed 1 Paclitaxel 1 Neoadjuvant Therapy 1 Diphenhydramine 1 Cisplatin 1 Chemotherapy, Adjuvant 1 Chemoradiotherapy 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06182761 2023-12-27

WUKONG-9

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡